Clinical Trials

35 enrolled

Melanoma

NCT03818685 2024-02-12

BreastImmune03

95 enrolled

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT03068624 2024-01-25

Autologous CD8+ SLC45A2-Specific T Lymphocytes With Cyclophosphamide, Aldesleukin, and Ipilimumab in Treating Patients With Metastatic Uveal Melanoma

34 enrolled

Uveal Melanoma

NCT03146650 2024-01-18

Nivolumab and Ipilimumab in Treating Patients With Metastatic/Recurrent ACC of All Sites and Non-ACC Salivary Gland Cancer

25 enrolled 14 charts

Head & Neck

Salivary Gland Neoplasms

NCT05150236 2023-12-15

ANZUP2001

93 enrolled

Genital Neoplasms, Male, Neoplasms, Neoplasms by Site, Prostatic Diseases, Prostatic Neoplasms, Urogenital Neoplasms

NCT05088889 2023-11-28

Maintenance Ipilimumab + Nivolumab Post Induction Chemotherapy + SBRT for First Line Treatment Stage IV Pancreatic Cancer

10 enrolled

Pancreatic Neoplasms

NCT02977052 2023-11-15

OpACIN-neo

186 enrolled

Melanoma

NCT03458455 2023-11-01

TREATMENT

200 enrolled

CNS

Brain Neoplasms

NCT03097939 2023-10-11

Phase 2 Trial of Ipilimumab and Nivolumab in Nasopharyngeal Carcinoma

113 enrolled

Head & Neck

Nasopharyngeal Carcinoma

NCT04591431 2023-10-03

ROME

BreastGastrointestinalThoracic

400 enrolled

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Gastrointestinal Neoplasms

NCT04741438 2023-08-30

RAR-Immune

Phase 3 Unknown

96 enrolled

Sarcoma

NCT03700905 2023-05-23

IMSTAR-HN

Phase 3 Unknown

276 enrolled

Head & Neck

Head and Neck Neoplasms

NCT03528408 2023-04-11

Study of Adjuvant Ipilimumab and Nivolumab in Subjects With High-risk Ocular Melanoma

52 enrolled

Uveal Melanoma, Melanoma

NCT04107168 2023-02-16

Microbiome Immunotherapy Toxicity and Response Evaluation

DermatologicGenitourinaryThoracic

1,800 enrolled

Kidney Neoplasms, Lung Neoplasms, Melanoma

NCT03682276 2022-12-13

PRIME-HCC

32 enrolled

Carcinoma, Hepatocellular

NCT03879122 2022-10-26

A Trial of Immunotherapy Strategies in Metastatic Hormone-sensitive Prostate Cancer

Phase 2/3 Unknown

135 enrolled

Prostatic Neoplasms

NCT04571632 2022-09-14

Luscid

36 enrolled

Carcinoma, Non-Small-Cell Lung

NCT04575922 2022-09-08

Nivolumab+Ipilimumab+RT in MSS mCRC

32 enrolled

Metastatic Microsatellite Stable Colorectal Cancer

NCT02437279 2022-04-15

OpACIN

20 enrolled

Melanoma

NCT03161756 2022-04-07

CHARLI

72 enrolled

Melanoma

NCT03177239 2022-02-16

UNISoN

85 enrolled

Carcinoma, Renal Cell

NCT03219775 2021-11-03

TITAN-TCC

169 enrolled

Carcinoma, Transitional Cell, Neoplasm Metastasis

NCT02948348 2021-09-16

Study to Nivolumab Following Preoperative Chemoradiotherapy

90 enrolled

Rectal Neoplasms

NCT04860076 2021-04-26

Open-label, Uncontrolled, Non-Interventional, Retrospective Study to Evaluate Molecular Determinants of Outcome to the Immune Checkpoint Inhibitors (Anti-PD-1/Anti-PD-L1 Monoclonal Antibodies) Treatment for Solid Tumors

400 enrolled

DermatologicThoracic

Lung Neoplasms, Melanoma

NCT02913417 2021-04-19

Yttrium90, Ipilimumab, & Nivolumab for Uveal Melanoma With Liver Metastases

26 enrolled

Uveal Melanoma

NCT04134182 2020-12-23

Nivolumab and Ipilimumab in T1aN0M0 Renal Cell Carcinoma Patients Ineligible for Surgical Treatment.

8 enrolled

Carcinoma, Renal Cell

NCT04136470 2020-08-10

BioForte Technology for in Silico Identification of Candidates for a New Microbiome-based Therapeutics and Diagnostics

130 enrolled

DermatologicThoracic

Carcinoma, Non-Small-Cell Lung, Melanoma, Neoplasms

NCT04145232 2020-08-10

AImmune - Artificial Intelligence Algorithm for Identification of Immunogenic Neoepitopes of Cancer to Predict and Boost Patient's Response to Immunotherapies.

30 enrolled

Carcinoma, Non-Small-Cell Lung, Neoplasms

NCT04131621 2020-04-15

CheCUP

194 enrolled

Tumor-Agnostic

Neoplasms, Unknown Primary

NCT03823625 2020-03-25

SQUINT

112 enrolled

Squamous-Cell Lung Cancer

NCT04250246 2020-01-31

NIBIT-ML1

184 enrolled

DermatologicThoracic

Carcinoma, Non-Small-Cell Lung, Melanoma

NCT04169867 2019-11-20

Polish Microbiome Map

1,160 enrolled

Melanoma, Neoplasms

NCT03784040 2019-04-08

da VINci

40 enrolled

Stomach Neoplasms

NCT03527251 2018-05-30

SEQUENCE

10 enrolled

Carcinoma, Non-Small-Cell Lung

NCT02982486 2017-11-01

A Phase II of Nivolumab Plus Ipilimumab in Non-resectable Sarcoma and Endometrial Carcinoma

60 enrolled

GastrointestinalSarcoma

Bone Neoplasms, Chondrosarcoma, Sarcoma, Osteosarcoma, Gastrointestinal Stromal Tumors, Desmoplastic Small Round Cell Tumor

NCT03098160 2017-10-30

Immunotherapy Study of Evofosfamide in Combination With Ipilimumab

DermatologicGastrointestinalGenitourinaryHead & Neck

69 enrolled

Squamous Cell Carcinoma of Head and Neck, Hypoxia, Melanoma, Pancreatic Neoplasms, Prostatic Neoplasms

NCT01565837 2016-02-01

SART

50 enrolled

Melanoma, Neoplastic Cells, Circulating, Neoplasm Metastasis

NCT02608437 2015-11-18

NIBIT-M4

19 enrolled